لخّصلي

It was found that antitumor medications independently contribute to positive platelet antibody screening results in patients with primary liver cancer, using regression models to reduce bias.Patients receiving combined anti-tumor drug therapy and peripheral blood cytopenia should have platelet antibody screening as soon as possible for the prevention and management of immune disorders, neoplastic anemia, thrombocytopenia, and ineffective platelet transfusion events during anti-tumor therapy.Notably, it was discovered that the degree of platelet antibody positively correlated with the anemia and thrombocytopenia severity in cases of hepatocellular carcinoma.

It was found that antitumor medications independently contribute to
positive platelet antibody screening results in patients with primary liver
cancer, using regression models to reduce bias. Notably, it was
discovered that the degree of platelet antibody positively correlated with
the anemia and thrombocytopenia severity in cases of hepatocellular
carcinoma. Patients receiving combined anti-tumor drug therapy and
peripheral blood cytopenia should have platelet antibody screening as
soon as possible for the prevention and management of immune
disorders, neoplastic anemia, thrombocytopenia, and ineffective platelet
transfusion events during anti-tumor therapy. To guarantee the smooth
advancement of tumor treatment, any emerging problems must be
identified and addressed as soon as possible.